The production of antibiotics by microbial fermentation has had a major impact on healthcare since the introduction of penicillin in the late 1940s. 
Over 260 new products have been approved for 230 indications, with more products in the pipeline. Monoclonal antibodies and vaccines are the leading product types today. Biologics represent over $120 billion in annual revenues in the US. CIB research addresses key issues in biologics production and antibody discovery. 

Participating CIB faculty members include: